Literature DB >> 15807724

Late onset vitiligo: a study of 182 patients.

Sunil Dogra1, Davinder Parsad, Sanjeev Handa, Amrinder Jit Kanwar.   

Abstract

The elderly constitute a large and rapidly growing segment of the population; however, there is complete lack of information about the epidemiology of vitiligo in this age group. To study the clinical and epidemiological profile of vitiligo in the elderly, we retrospectively analyzed the data of patients with vitiligo having onset of disease after 50 years of age attending the pigmentary clinic of our center. Of the 182 patients, 87 (47.8%) were males and 95 (52.2%) were females. The mean age of onset of disease was 55 +/- 2.3 years. Vitiligo vulgaris was the most common (83.5%) followed by focal (5.5%), segmental (4.4%), acrofacial (3.8%), mucosal (2.2%), and universal (0.5%). The most common site of onset was the head and neck (24.2%) followed by the upper limbs (23%), trunk (22%), lower limbs (17.6%), oral/genital mucosae (7.1%), and flexures (6%). Koebner's phenomenon was observed in 14.8% while leukotrichia was present in 47.3% of the patients. Halo nevi were observed in 3.8% of patients, and vitiligo was stable in 64.8%. Twenty-nine (15.9%) patients had family history of vitiligo. Associated autoimmune autoimmune/endocrine disorders were present in 39 (21.4%) of the patients. Differences in disease characteristics compared with vitiligo in children and young adults are discussed.

Entities:  

Mesh:

Year:  2005        PMID: 15807724     DOI: 10.1111/j.1365-4632.2004.01948.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  9 in total

1.  Evaluation of Histologically and Histochemically Proven Cases of Vitiligo and its Correlation with CD4+ and CD8+ Lymphocyte Counts using Flow Cytometry.

Authors:  Moninder Kaur; Permeet Kaur Bagga; Tejinder Kaur; Amarjit Singh Kataria
Journal:  J Clin Diagn Res       Date:  2017-05-01

Review 2.  Therapeutic implications of autoimmune vitiligo T cells.

Authors:  Kepa Oyarbide-Valencia; Jasper G van den Boorn; Cecele J Denman; Mingli Li; Jeremy M Carlson; Claudia Hernandez; Michael I Nishimura; Pranab K Das; Rosalie M Luiten; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2006-05-06       Impact factor: 9.754

3.  Anti-thyroid peroxidase antibody in vitiligo: a prevalence study.

Authors:  R Dash; A Mohapatra; B S Manjunathswamy
Journal:  J Thyroid Res       Date:  2015-01-11

4.  Adult Onset Vitiligo: Multivariate Analysis Suggests the Need for a Thyroid Screening.

Authors:  L Lazzeri; R Colucci; A Cammi; F Dragoni; S Moretti
Journal:  Biomed Res Int       Date:  2016-09-22       Impact factor: 3.411

5.  A Nationwide, Multicentric Case-Control Study on Vitiligo (MEDEC-V) to Elicit the Magnitude and Correlates.

Authors:  Nilendu Sarma; Sayantani Chakraborty; Shital Poojary; B M Shashi Kumar; Lalit Kumar Gupta; Leelavathy Budamakuntla; Leishiwon Kumrah; Suchibrata Das; Ajay Govindrao Ovhal; Nirmal Kumar Mandal; Shuvankar Mukherjee; T V Anoop; Binod Kumar Thakur; L Eswari; Joan Felicita Samson; Krina Bharat Patel; Rajesh Rajagopalan; Sanjeev Gupta; Tejinder Kaur
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

6.  Vitiligo following COVID-19: A case report and review of pathophysiology.

Authors:  Alexandra F Schmidt; Alexandra Rubin; David Milgraum; Cindy Wassef
Journal:  JAAD Case Rep       Date:  2022-02-10

Review 7.  Diet and Vitiligo: The Story So Far.

Authors:  Rajoshee R Dutta; Tanishq Kumar; Nishikant Ingole
Journal:  Cureus       Date:  2022-08-28

8.  Gender differences in clinicoepidemiological features of vitiligo: a cross-sectional analysis.

Authors:  Sharmila Patil; Manjyot Gautam; Nitin Nadkarni; Neha Saboo; Kiran Godse; Maninder Singh Setia
Journal:  ISRN Dermatol       Date:  2014-02-13

9.  A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients.

Authors:  Fariba Iraji; Seyed Hossin Banihashemi; Gita Faghihi; Zabihollah Shahmoradi; Nabet Tajmirriahi; Safoura Bokaie Jazi
Journal:  Adv Biomed Res       Date:  2017-03-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.